BCL2 and melanoma: BH3 mimetics antagonize the action of anti-apoptotic proteins such as BCL2, MCL1 etc. Previous studies by our group and others indicate that combination treatments targeting BCL2 family proteins, particularly MCL1, may be a promising option in melanoma [17,19,23].